This category page covers biotechnology and pharmaceutical companies developing ER stress and unfolded protein response (UPR) modulators specifically for Parkinson's disease. The ER stress pathway is a central pathological mechanism in PD, where protein misfolding, calcium dysregulation, and mitochondrial dysfunction converge to trigger chronic ER stress and ultimately dopaminergic neuron death. [1]
Targeting ER stress and the UPR offers disease-modifying potential by addressing proteostasis failure—a root cause of neurodegeneration rather than just symptomatic relief.
The ER stress/UPR pathway is particularly relevant for Parkinson's disease because: [2]
| Approach | Description | Companies |
|---|---|---|
| Chemical Chaperones | Enhance ER folding capacity (TUDCA, PBA) | Amylyx |
| PERK/eIF2α Modulators | Inhibit pro-apoptotic signaling | Research-stage |
| IRE1 RNASE Modulators | Reduce chronic RNase activity | Research-stage |
| ATF6 Activators | Promote adaptive chaperone expression | Research-stage |
| Anti-apoptotic Agents | Block CHOP-mediated apoptosis | Research-stage |
Amylyx Pharmaceuticals (NASDAQ: AMLX) is the only company with an approved ER stress-modulating drug relevant to Parkinson's disease.
Relyvrio therapeutic page
Amylyx company page
Cyclo Therapeutics is developing cyclobenzaprine derivatives targeting ER stress in neurodegenerative diseases.
Cyclo Therapeutics company page
| Company | Program | Mechanism | PD Status |
|---|---|---|---|
| Denali Therapeutics | DNL343 | LRRK2 inhibitor with ER stress modulation | Phase 1 |
| Prevail Therapeutics | PR001 | AAV-GBA1 (reduces ER stress from GCase deficiency) | Phase 1/2 |
| Vanqua Bio | VQVN | LRRK2 inhibitor | Phase 2 |
| Gain Therapeutics | GT-02287 | GCase activator | Preclinical |
Denali Therapeutics has an ER stress modulation component to their LRRK2 inhibitor program.
Denali Therapeutics company page
Prevail Therapeutics (acquired by Eli Lilly) is developing gene therapy for GBA-associated PD.
Prevail Therapeutics company page
Wang et al. ER stress and unfolded protein response in neurodegenerative diseases. Neurobiology of Aging. 2020. ↩︎
Hashimoto et al. ER stress in Parkinson's disease. Journal of Parkinson's Disease. 2021. ↩︎